Hims vs Oak Longevity: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
Hims beats Oak Longevity overall, scoring 7.9/10 vs 7.5/10. Oak Longevity is more affordable at $133/mo vs $199/mo. Choose Hims for men who want a well-known publicly-traded brand and fda-appr. Choose Oak Longevity for budget-conscious users who want one of the cheapest compound.
A side-by-side look at Hims and Oak Longevity to help you decide. We compare them on:
- •Starting price per month
- •Our overall score, out of 10
- •Medication type, brand-name or compounded
- •Whether they accept insurance
- •Who each one is best for
Hims
#9 of 53The household name in men's telehealth, publicly traded as Hims & Hers Health (NYSE: HIMS). In 2026 Hims added FDA-approved brand-name Wegovy (injection and pill) and Ozempic through a direct Novo Nordisk partnership, alongside their existing compounded semaglutide program. Brand recognition and product breadth are real strengths. The trade-off: Hims' verified Trustpilot rating is 3.0 stars across 8,286 reviews (May 2026), significantly below smaller competitors like Henry Meds (4.5) or Eden Health (4.5). The 1-star pool is 28%, the highest 1-star rate in our table, clustered around subscription/billing complaints.
Visit HimsOak Longevity
#25 of 53Telehealth platform offering compounded semaglutide and tirzepatide at the lower end of market pricing, alongside an oral Wegovy option, brand-name FDA-approved GLP-1s, and a longevity stack (NAD+, Glutathione, Sermorelin, Tesamorelin). Distinctive non-subscription billing, patients pay each month manually rather than auto-renew.
Visit Oak Longevity| Feature | Hims | Oak Longevity |
|---|---|---|
| Our Score | 7.9/10 | 7.5/10 |
| Starting Price | $199/mo | $133/mo |
| Medication Type | Both | Both |
| Insurance Accepted | No | No |
| Best For | Men who want a well-known publicly-traded brand and FDA-approved Wegovy through the 2026 Novo Nordisk partnership, but should know going in that Hims' customer-experience signal is weaker than smaller competitors | Budget-conscious users who want one of the cheapest compounded GLP-1 entries plus a no-subscription billing model and a longevity-stack add-on (NAD+, Sermorelin) |
| Watch out for | Trustpilot rating is 3.0 stars / 8,286 reviews (May 2026), significantly below Henry Meds (4.5), Eden Health (4.5), Yucca Health (4.6), MEDVi (4.4). The lowest customer-experience signal of any major brand we track. | Brand-name pricing ($1,200-$1,500/mo) is significantly above market, NovoCare sells Wegovy direct at $349/mo and LillyDirect has Zepbound at $299/mo. Use Oak for its compounded tiers and buy brand-name direct |
| Ranking | #9 | #25 |
| Get started | Visit Hims | Visit Oak Longevity |
Pros & Cons Compared
Hims
Pros
- +Publicly traded company (NYSE: HIMS), SEC-filed financials, regulatory accountability that private competitors don't have.
- +2026 Novo Nordisk partnership, FDA-approved Wegovy injection, Wegovy pill, and Ozempic now available directly through Hims. Real brand-name access from a single platform.
- +$199/mo all-inclusive for compounded semaglutide, including consultations and shipping.
- +Polished app and web experience, among the best user interfaces in men's telehealth.
- +8,286 verified Trustpilot reviews is the second-largest review volume in our table (after Henry's 12,461), significant real-world adoption.
Cons
- −Trustpilot rating is 3.0 stars / 8,286 reviews (May 2026), significantly below Henry Meds (4.5), Eden Health (4.5), Yucca Health (4.6), MEDVi (4.4). The lowest customer-experience signal of any major brand we track.
- −28% of Trustpilot reviews are 1-star, the highest 1-star rate in our table. Top complaint themes: subscription handling, unexpected charges, customer service responsiveness.
- −Hims reviews span ALL their products (ED, hair loss, mental health, weight loss), not just GLP-1. But the rating still applies because most users don't separate experiences by product.
- −'Hims Oral Kit' is NOT a GLP-1, it's a non-GLP-1 metabolic combination (metformin + bupropion + topiramate + B12 + naltrexone). Easy to confuse with their compounded semaglutide. Read the product page carefully before signing up.
- −Brand Wegovy at $599/mo is not competitive with LillyDirect/NovoCare cash prices or with Hers ($149/mo for the same product via the same Novo partnership).
- −Generic high-volume support, large patient base means less personalized attention than smaller competitors.
Oak Longevity
Pros
- +$133/mo for compounded semaglutide is among the cheapest entries on the market, Sesame Care ($99) is lower, but Oak undercuts most mid-tier platforms
- +No-subscription model, patients are not auto-charged each month, choose to renew manually. Reduces unwanted recurring charges
- +Compounded tirzepatide at $199/mo is competitively priced for a GLP-1+GIP dual agonist
- +Broadest medication mix on the platform: compounded sema + tirz, oral Wegovy, brand Wegovy/Ozempic/Zepbound/Mounjaro, plus longevity peptides (NAD+, Glutathione, Sermorelin, Tesamorelin)
- +Money-back guarantee if not approved by physician, useful safety net for borderline-eligibility patients
- +Free shipping and free health coaching included in every program
Cons
- −Brand-name pricing ($1,200-$1,500/mo) is significantly above market, NovoCare sells Wegovy direct at $349/mo and LillyDirect has Zepbound at $299/mo. Use Oak for its compounded tiers and buy brand-name direct
- −No published lab panels and no specialty (obesity medicine) physicians disclosed, clinical oversight is lighter than lab-driven platforms
- −The 'up to 50% cheaper than competitors' marketing claim is unverified and inconsistent, judge Oak on its posted prices, which are genuinely low, not on the slogan
- −The longevity add-ons (NAD+, Sermorelin, Tesamorelin) have limited clinical evidence for weight loss specifically, if weight loss is the goal, the GLP-1 alone does the work and the stack is optional
- −Newer brand without disclosed company history, founding date, or executive team on landing pages
- −Three-month plans are billed upfront, start on the 1-month plan if you're testing the platform, then bundle once it fits
Our Verdict
Hims edges out Oak Longevity with a score of 7.9/10 vs 7.5/10. If budget is your priority, Oak Longevity starts at $133/mo compared to Hims's $199/mo. Choose Hims if you want: men who want a well-known publicly-traded brand and fda-approved wegovy through the 2026 novo nordisk partnership, but should know going in that hims' customer-experience signal is weaker than smaller competitors. Choose Oak Longevity if you want: budget-conscious users who want one of the cheapest compounded glp-1 entries plus a no-subscription billing model and a longevity-stack add-on (nad+, sermorelin).
Still undecided? Editor's Featured Pick
TrimRx
$149/mo · 7.8/10 · Compounded
If neither Hims nor Oak Longevity feels like the right fit, our featured pick across all 53 GLP-1 telehealth providers is TrimRx. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $149/mo that stays the same at every dose.
Read Full Reviews
Related comparisons
Other matchups readers comparing Hims or Oak Longevity tend to look at next.
- Hims vs MEDVi$179/mo
- Hims vs Hers$199/mo
- Hims vs Shed$199/mo
- Oak Longevity vs Found$129/mo
- Oak Longevity vs GobyMeds$169/mo
- Oak Longevity vs bmiMD$119/mo
Not sure which one is right for you?
Answer a few quick questions and we'll match you to the best GLP-1 provider for your needs. Or keep exploring below.